Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of AG0302-COVID19 DNA Vaccine in Healthy Adults
NCT04527081Phase 2Completed
- Sponsor
- AnGes, Inc.
- Start
- Aug 2020
- Primary completion
- Nov 2020
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of AG0302 in coronavirus disease 2019 (COVID-19), sponsored by AnGes, Inc.. Started Aug 2020; status: completed.
02
Drugs
AG0302
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04527081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04527081.